Home > Healthcare > Pharmaceuticals > Finished Drug Form > Pregnancy Medication Market

Pregnancy Medication Market Trends

Report ID: GMI5385
Published Date: Oct 2022
Report Format: PDF

Download Free Sample

Pregnancy Medication Market Trends

The intake of other medications and the possible side effects and health risks associated with them may limit the pregnancy medication market value. A significant share of pregnant women consumes over-the-counter drugs for several comorbidities, such as CVDs, which are one of the leading causes of death among pregnant women. These medications may also lead to premature birth, low birth weight, stillbirth, and other complications, which may downsize the market share.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market size for pregnancy medication exceeded USD 33 billion in 2022 and is projected to exhibit around 13% CAGR from 2023 to 2032 owing to the surging incidences of complexities associated with pregnancy and childbirth.

Nutritional supplements segment was worth over USD 16.5 billion in 2022 and is anticipated to amass significant market share by 2032 due to the proven benefits of nutritional supplements in supporting healthy fetal growth and preventing the prospects of neural tube defects.

Retail pharmacy segment is predicted to hold around 28% market share by 2032, driven by the availability of a wide range of health products and customized prescription and treatment at affordable prices.

Notable players in the pregnancy medication MARKET are Alkem Laboratories Limited, Piramal Enterprises Limited, F.Hoffman-La Roche Ltd, Pfizer, Dr. Reddy’s Laboratories, Cipla Inc, Alembic Pharmaceuticals Ltd, Lupin Limited, Glenmark Pharmaceuticals Ltd, Viatris Inc., (Mylan Inc.), Amgen Inc., and others.